

Novartis Entresto® indicated for treatment of hypertension in China

Jun 10, 2021

Novartis today announced that Entresto® (sacubitril/valsartan) has received a new indication in China for the treatment of patients with essential hypertension, a disease affecting approximately 245 million adults in the country¹. This National Medical Products Administration (NMPA) decision follows the 2017 approval of Entresto for the treatment of heart failure with reduced ejection fraction (HFrEF).

- The prevalence of hypertension in China is expected to rise to approximately 300 million² by 2025 with control rates generally lower than in other parts of the world (15% vs approximately 52% in the US)^{1,3}
- This new indication makes Entresto the first new therapy for hypertension in China in over ten years. Entresto was also approved for the treatment of hypertension in Russia in February 2021.
- Hypertension can damage the heart, kidneys, blood vessels and other organs⁴ and is a major risk factor for cardiovascular events, as well as a leading cause of mortality and morbidity in Asia and across the world accounting for approximately 1.8 million deaths annually in China alone⁵

Source URL: <https://prod1.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china>

List of links present in page

1. <https://prod1.novartis.com/news/novartis-entresto-indicated-treatment-hypertension-china>